Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma, not otherwise specified (DLBCL-NOS), by prior biopsy.
Part 1 participants: Has relapsed or refractory DLBCL after at least 2 prior systemic DLBCL therapies; Part 2 participants: Has relapsed or refractory DLBCL after at least 1 prior systemic DLBCL therapy.
Is ineligible for or progressed after autologous stem cell transplant (ASCT) or chimeric antigen receptor T-cell (CAR-T) therapy.
Has locally confirmed cluster of differentiation 19 (CD19) expression in tumor tissue obtained after disease progression on CD19-targeting therapy, if had disease progression after CD19-targeting therapy.
Has radiographically measurable DLBCL per Lugano response criteria.
Has provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.
If human immunodeficiency virus (HIV)-infected, has well-controlled HIV on antiretroviral therapy.
If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy.
If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.
You may not be if
Has a diagnosis of primary mediastinal B-cell lymphoma.
Has received a solid organ transplant.
Has a known or suspected history of hemophagocytic lymphohistiocytosis (HLH).
Has a rare type of DLBCL.
Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
Has a history of serious cardiovascular or cerebrovascular diseases.
Has a demyelinating form of Charcot-Marie-Tooth disease.
Has ongoing corticosteroid therapy (in dosing exceeding 30 mg daily of prednisone equivalent).
Has a known additional malignancy that is progressing or required active treatment in the past 3 years.
Has a history or presence of clinically relevant central nervous system (CNS) diseases.
Has known active CNS lymphoma or involvement of CNS with DLBCL.
Has an active autoimmune disease that required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed.
Has an active infection requiring systemic therapy.
Has prior allogeneic stem cell transplantation and has acute graph versus host disease (GVHD), ongoing chronic GVHD, or requires systemic immunosuppression for treatment/prophylaxis of GVHD.
Has not adequately recovered from surgery or has ongoing surgical complications.
Has been found to be primary refractory to monomethyl auristatin E (MMAE)-containing agents